ChunLab Inc
CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company's platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson's diseases… Read more
ChunLab Inc (311690) - Total Assets
Latest total assets as of September 2025: ₩76.34 Billion KRW
Based on the latest financial reports, ChunLab Inc (311690) holds total assets worth ₩76.34 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ChunLab Inc - Total Assets Trend (2017–2024)
This chart illustrates how ChunLab Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ChunLab Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
ChunLab Inc's total assets of ₩76.34 Billion consist of 77.1% current assets and 22.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 8.3% |
| Accounts Receivable | ₩334.12 Million | 0.3% |
| Inventory | ₩128.75 Million | 0.1% |
| Property, Plant & Equipment | ₩8.91 Billion | 8.9% |
| Intangible Assets | ₩12.50 Billion | 12.6% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how ChunLab Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ChunLab Inc's current assets represent 77.1% of total assets in 2024, a decrease from 89.1% in 2017.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, up from 0.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 12.6% of total assets.
ChunLab Inc Competitors by Total Assets
Key competitors of ChunLab Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
ChunLab Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ChunLab Inc generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ChunLab Inc is currently not profitable relative to its asset base.
ChunLab Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.91 | 3.11 | 13.68 |
| Quick Ratio | 3.90 | 3.09 | 13.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩43.00 Billion | ₩ 29.97 Billion | ₩ 38.09 Billion |
ChunLab Inc - Advanced Valuation Insights
This section examines the relationship between ChunLab Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 9.3% |
| Total Assets | ₩99.61 Billion |
| Market Capitalization | $24.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values ChunLab Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ChunLab Inc's assets grew by 9.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ChunLab Inc (2017–2024)
The table below shows the annual total assets of ChunLab Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩99.61 Billion | +9.31% |
| 2023-12-31 | ₩91.13 Billion | -0.29% |
| 2022-12-31 | ₩91.39 Billion | -21.46% |
| 2021-12-31 | ₩116.36 Billion | +58.60% |
| 2020-12-31 | ₩73.36 Billion | +117.43% |
| 2019-12-31 | ₩33.74 Billion | +162.90% |
| 2018-12-31 | ₩12.83 Billion | -14.37% |
| 2017-12-31 | ₩14.99 Billion | -- |